The Price Information Dossier is a central element in the pricing of new drugs in the national territory. The MAPESolutions team is sensitive to this very important step in launching new products. To this end, in all projects we carry out a major situational diagnosis, identifying all the possibilities of categorization in compliance with current legislation. Once this stage is consolidated, all possible ways and their respective risks for the pricing rationale are discussed. Allied to the solid knowledge of HTA, our team elaborates a robust DIP, both from a technical-scientific point of view as well as with regard to the strategic rationale of the product launch. Our service only ends at the end of pricing. In other words, we give all the support of the dossier in the SAMMED – Tracking System of Medicine Market – system, going through all the procedural steps of the CMED – Medicines Market Regulation Chamber, until the final decision of the body.